Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524312 | 0.88 | TDP1 (0.58) | TSHRSMN1; SMN2HSD17B10TDP1KCNMA1 | |
| SCHEMBL27395653 | 0.83 | TSHR (0.58) | TSHRSMN1; SMN2HSD17B10TDP1KCNMA1 | |
| SCHEMBL8262644 | 0.83 | TSHR (0.58) | TSHRSMN1; SMN2HSD17B10TDP1KCNMA1 | |
| SCHEMBL27416975 | 0.83 | TSHR (0.58) | TSHRSMN1; SMN2HSD17B10TDP1KCNMA1 | |
| SCHEMBL3045742 | 0.81 | TSHR (0.56) | TSHRSMN1; SMN2HSD17B10TDP1KCNMA1 | |
| SCHEMBL11591038 | 0.80 | KCNMA1 (0.65) | TSHRSMN1; SMN2HSD17B10TDP1KCNMA1 | |
| SCHEMBL18725484 | 0.80 | TSHR (0.55) | TSHRSMN1; SMN2HSD17B10TDP1KCNMA1 | |
| SCHEMBL102957 | 0.79 | MAPT (0.49) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 | |
| SCHEMBL4725240 | 0.79 | TDP1 (0.48) | TSHRSMN1; SMN2HSD17B10TDP1KCNMA1 | |
| SCHEMBL4725194 | 0.79 | TDP1 (0.48) | TSHRSMN1; SMN2HSD17B10TDP1KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022068933-A1 | COMPOUNDS AND METHODS OF TREATING DISEASES | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-07 | — | — | WO | disclosed |
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| CN-101454292-A | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | CN | disclosed |
| CN-101405000-A | 2-imino-benzimidazoles | ABBOTT LAB (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-2004613-A2 | BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2008-12-24 | — | — | EP | disclosed |
| EP-1983992-A2 | 2-IMINO-BENZIMIDAZOLES | Abbott Laboratories (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007115077-A2 | BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
| US-4117165-A | ANTIULCER, HYPOTENSIVE AGENTS | WILLIAM H. RORER, INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | TSHR 467/4885SMN1; SMN2 3250/4885HSD17B10 3994/4885 |
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | TSHR 2626/4885SMN1; SMN2 824/4885HSD17B10 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.